For patients diagnosed with the aggressive HER2‐positive form of BC, the use of AC, particularly in conjunction with trastuzumab (TTZ), markedly enhances both disease‐free survival and overall survival rates [2]. This evidence concerns the gene ERBB2 and breast cancer.